Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL-17 Triggers Invasive and Migratory Properties in Human MSCs, while IFNy Favors their Immunosuppressive Capabilities: Implications for the "Licensing" Process.

Stem cell reviews and reports - 1 Dec 2020

Du-Rocher Bárbara, Binato Renata, de-Freitas-Junior Julio Cesar Madureira, Corrêa Stephany, Mencalha André Luiz, Morgado-Díaz José Andrés, Abdelhay Eliana

Abstract excerpt

Mesenchymal stromal cells (MSCs) were first used as a source for cell therapy in 1995; however, despite their versatility and unambiguous demonstration of efficacy and safety in preclinical/phase I studies, the positive effect of MSCs in human phase III studies did not resemble the success obtained in mouse models of disease. This dissonance highlights the need to more thoroughly study the immunobiology of MSCs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Movement
Share to Cytokines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppression Therapy

Share to Inflammation Mediators

Share to Interferon-gamma

Share to Interleukin-17

Share to Lymphocyte Culture Test, Mixed

Share to Mesenchymal Stem Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 33067729
DOI: 10.1007/s12015-020-10051-4
PMCID: PMC7667142

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL-17 Triggers Invasive and Migratory Properties in Human MSCs, while IFNy Favors their Immunosuppressive Capabilities: Implications for the "Licensing" Process.PMID 33067729Read ↗

Immunomodulatory potential of cytokine-licensed human bone marrow-derived mesenchymal stromal cells correlates with potency marker expression profileSemantic proximity Read ↗

The immunomodulatory function of mesenchymal stem cells: mode of action and pathwaysSemantic proximity Read ↗

Mesenchymal stem cells—the master immunomodulatorsSemantic proximity Read ↗

The Role of Mesenchymal Stem/Stromal Cells Secretome in Macrophage Polarization: Perspectives on Treating Inflammatory DiseasesSemantic proximity Read ↗

Unveiling the functional heterogeneity of cytokine-primed human umbilical cord mesenchymal stem cells through single-cell RNA sequencingSemantic proximity Read ↗

Characterizing the secretome of licensed hiPSC-derived MSCsSemantic proximity Read ↗

Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatmentSemantic proximity Read ↗

Mesenchymal Stem/Stromal Cells: A Review for Its Use After Allogeneic Hematopoietic Stem Cell TransplantationSemantic proximity Read ↗

The microenvironment resulting from the co-culture of human amniotic fluid-derived mesenchymal stem cells with peripheral blood mononuclear cells differs between type 1 diabetes mellitus patients and healthy individualsSemantic proximity Read ↗

Immunomodulation by Mesenchymal Stem CellsSemantic proximity Read ↗

Licensing Microgels Prolong the Immunomodulatory Phenotype of Mesenchymal Stromal CellsSemantic proximity Read ↗

Mesenchymal stem cells modulate IL-17 and IL-9 production induced by Th17-inducing cytokine conditions in autoimmune arthritis: an explorative analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.